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Abstract The pathophysiology of pituitary-associated
headache is unknown, although structural and functional
features of the tumour are proposed mechanisms. The
objective of this study was to evaluate whether headache in
a population with pituitary micro-adenomas was related to
hyperprolactinemia. We recruited 29 patients with micro-
prolactinoma and headache: 16 with migraine (group A)
and 13 with tension-type-headache (group B). The pro-
lactin (PRL) levels measured during attacks of headache
were significantly higher in nine patients (56%) of group A
and in one patient (8%) of group B. In four of the nine
patients of group A, PRL increased after thyrotropin-
releasing-hormone (TRH) test and induced severe attacks.
After dopamine-agonist (DA) treatment, the headache
improved in seven (44%) patients of the group A and in
two (15%) patients of the group B. Three of the four
patients in whom the TRH-test induced headache attacks,
improved after DA treatment. We suggest that hyperpro-
lactinemia may contribute to development of pain in
migraine subgroups and further TRH-test could be used to
predict which patients could benefit by DA therapy.
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Introduction
The clinical presentation of pituitary adenomas is dependent
upon both structural and functional properties of the tumour
[1]. It is unclear whether headache is a structural or a func-
tional consequence of pituitary disease [2]. Nevertheless,
even if a structural mode may be a plausible mechanism in
cases of pituitary macro-adenomas and cavernous sinus
invasion, it is not an acceptable explanation for micro-ade-
nomas. Few studies reported that patients with micro-
adenoma may suffer from severe headache, while patients
with macro-adenoma may not have headache. This suggests
that mass effect of the tumor is not always correlated to the
presence or intensity of the headache [3] and that biochem-
ical activity may be important in some forms of pituitary
tumor-associated headache [4]. The hypothalamic–hypo-
physial axis dysfunction is believed to be implicated in the
pathogenesis of primary headache syndromes [5]. A variety
of headache phenotypes has been associated with pituitary
tumors [6–9]. Some authors suggest a hypersensitivity of
dopamine receptors, based on the observation that, some
headaches showed higher prolactin (PRL) after taking
dopaminergic agents [10]. Other authors suggested a
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serotoninergic hyperfunction rather than dopaminergic
dysfunction. Serotonin is known to increase PRL secretion
and decrease thyrotropin (TSH) secretion [11]. Therefore,
dopaminergic hypofunction could be the consequence of
serotoninergic hyperfunction, because of the inhibitory
effect of serotonin on dopamine neurons. In fact, in some
patients with headache, the treatment with dopamine-ago-
nists (DAs) can determine various responses, with worsening
in some cases and improvement in others [12, 13]. The aim of
this study was to evaluate whether high PRL levels may be
correlated to some type of headaches in pituitary, tumor-
associated.
Patients and methods
After complete description of the study, all patients gave
their informed consent, in accordance with the official
standards of the 1964 declaration of Helsinki, local laws
and regulations, was approved by the Ethical Committee of
‘‘S. Giovanni di Dio’’ Hospital, Crotone, Italy. We
recruited 29 (26 women and 3 men) unselected patients
who arrived for the first time to the headache centre suf-
fering from episodic migraine or episodic tension-type
associated with microprolactinoma, in line with the current
ICHD-II criteria [14], between February 2003 and May
2007. Patients with microprolactinoma and atypical
migraine or other forms of headache were excluded from
the study. Our headache centre is a second-level centre
with neurologists, experts in headache disorders. Patients
were recruited after a first-level check-up carried out by a
neurologist, a neurosurger or an endocrinologist. The
patients were successively divided in to two groups:
• Group A microprolactinoma and migraine (17 patients).
• Group B microprolactinoma and tension-type headache
(12 patients).
At the beginning of the study, six patients had oligo-
amenorrhoea (4 group A and 2 group B), two galactorrhea
(1 group A and 1 group B) and 13 both galactorrhea and
oligo-amenorrhoea (9 group A and 4 group B). Headache
and amenorrhoea or galactorrhea were coincident in seven
patients of the group A and one patient of the group B,
while three patients of the group A and five of the group B
were not coincident. Only in one patient of group A, we
had no sure anamnestic data. Demographic and clinical
characteristics of both groups are presented on Table 1.
All patients underwent the following tests: magnetic res-
onance imaging (MRI) with gadolinium of the brain, X-ray
scan of the neck, odontological evaluation, general blood test,
hormonal screening [luteinizing hormone (LH), follicle-
stimulating hormone (FSH), estradiol, progesterone, T3, T4,
thyrotropin (TSH), cortisol, ACTH, testosterone, growth
hormone (GH), insulin growth factor 1 (IGF1), somatostatine
hormones (SH) and PRL profile]. PRL was evaluated by
indwelling catheter inserted into an antecubital vein, at times
0–30 and 60 min. There was no significant difference between
the three values, but we considered as ‘‘basal’’, the mean value
of PRL at 60 min, at least in two consecutive attacks of
headaches. Serum PRL was tested with immunofluorometric
assay (TOSOH Bioscence, Japan). Values over 29.2 ng/mL
for women and 17 ng/mL for men can be referred as being
abnormal [15]. TSH and PRL were evaluated in basal condi-
tion and at least in two headache attacks. We considered as
pathological when two consecutive results were higher than
normal. The blood samples were all taken in the same labo-
ratory. All MRI examinations included coronal and sagittal
T1-weighted spin-echo sequences with a maximum slice
thickness of 3 mm, before and after gadolinium-base contrast
medium. The protocol excluded pituitary macroadenomas
(Ø C 10 mm) with/or without cavernous sinus invasion.
The assessment of the tumor volume, was calculated
using Cavalieri’s principle and calculated after performing
measurements of tumor diameter in three orthogonal
planes, using the following equation [16]:
Volume ¼ ½4=3 p ða=2  b=2  c=2Þ
The presence and degree of cavernous sinus invasion
were also documented on the basis of two different
parameters [17]:
1. Encasement of the internal carotid artery.
2. Extension of the tumor into the compartment of the
cavernous sinus.
Table 1 Demographic and clinical features of 29 patients with
headaches and microprolactinoma
Group A Group B
No. (%) 17 (59) 12 (41)
Age (years)
Mean ± SD 34.6 ± 4.2 39.6 ± 4.3
Range 29–44 30–46
Sex (F/M) 15/1 11/2
Duration of disease
Mean ± SD 7.8 ± 2.2 10.3 ± 2.8
Range 3–12 4.8–14
Attacks for month
Mean ± SD 6.4 ± 1.8 9.1 ± 2.6
Range 3.3–9.4 3.8–12
Galactorrhea, No. (%) 1/17 (6) 1/12 (8)
Oligo-amenorrhoea, No. (%) 4/17 (23) 2/12 (17)
Galactorrhea and/or
Oligo-amenorrhoea, No. (%)
9/17 (53) 4/12 (33)
Group A microprolactinoma and migraine, group B microprolacti-
noma and tension-type-headache
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Other criteria excluded patients receiving antiparkinsonian
treatment or others drugs that could influence PRL levels.
The patients, successively, were evaluated with TSH
and PRL-responses to thyrotropin-releasing-hormone
(TRH) test. All patients were given cabergoline at a start
dosage of 0.25 mg twice a week. Some patients required,
successively, an increase to 0.5 mg twice a week.
Patients compiled a diary from 3 months before to
3 months after treatment with cabergoline, where they
recorded the date, duration and intensity of each attack of
headache.
Data were expressed as mean ± SD. The differences
between two groups were compared using a non-parametric
Wilcoxon rank sun test. Differences or changes were
considered to be statistically significant if the P values
were less than or equal to a level of 5%.
Results
During a period of 4 years, from 2003 to 2007, we recruited
29 patients (26 females and 3 males), affected from migraine
(group A, 17 patients) or tension-type headache (group B, 12
patients) associated with microprolactinoma. The mean age
was 34.6 ± 4.2 in the group A and 39.6 ± 4.3 in the group
B. The mean duration of headaches was 7.8 ± 2.2 years in
the group A and 10.3 ± 3.8 years in the group B, while
attacks frequency/month was, respectively, 6.4 ± 1.8 in the
group A and 9.1 ± 2.6 in the group B. Basal serum levels of
LH, FSH, progesterone, estradiol, cortisol, ACTH, GH, T3,
T4, TSH cortisol, ACTH, testosterone, SH, GH and IGF1
were normal in both groups. The mean ‘‘basal’’ level of
serum PRL was moderately higher in the group A, although
the difference between two groups was not statistically sig-
nificant (group A vs group B: 118.6 ± 10.8 vs 106.9 ± 9.7;
p = 0.215). During headache attacks, we registered a
significant PRL increase from baseline, only in patients
of the group A (attacks vs baseline: 150.6 ± 16.8 vs
118.6 ± 10.8 ng/mL; p \ 0.005), while in the group B, no
significant increase of PRL levels from baseline were reg-
istered in all patients (attacks vs baseline: 108.7 ± 8.7 vs
106.9 ± 9.7 ng/mL; p = 2.5). After TRH-test, PRL levels
were significantly increased in patients of group A vs basal
conditions (TRH-test vs baseline: 161.3 ± 27.4 vs
118.6 ± 10.8 ng/mL; p \ 0.001), but not versus PRL levels
during migraine (TRH-test vs attacks 161.3 ± 27.4 vs
150.6 ± 16.8 ng/mL; p \ 0.12). Moreover, after TRH-test,
no differences of PRL values were observed in patients
of group B (TRH-test vs baseline: 107 ± 9.4 vs
106.9 ± 9.7 ng/mL; p = 1.73). No significant variations of
TSH levels were documented in both groups in basal con-
ditions, during migraine attacks or after TRH-test. In
the group A, after cabergoline treatment, the PRL mean
was 74 ± 6.8 ng/mL and the migraine frequency attacks,
evaluated by patients’ diaries, improved in eight patients
(n = 8/17, 47%), were unchanged in three (n = 3/17,
17.6%), worsened in two (n = 2/17, 11.7%) and in four
(n = 4/17, 23.5%) cases migraines changed characteristics
and became a tension-type headache. In the group B, after
DAs treatment, the PRL mean was 68.2 ± 5.1 ng/mL; the
headaches were unchanged in most cases (n = 11/12,
91.6%), only in one patient, we observed a moderate
improvement (about 30% frequency/month attacks).
Moreover, after DAs treatment, we observed a signifi-
cant improvement of galactorrhea in both groups of
patients, while menstrual irregularity improved in 15
patients (group A: 11 and group B: 4) and was unchanged
in the remaining patients.
Successively, we evaluated in each patient of both
groups, the PRL-response during headache attacks. In
seven patients (41%) of the group A, we registered a small
and not significant PRL increase ‘‘no-responder’’ (baseline
vs attacks: 127 ± 21.4 vs 136.8 ± 19.8 ng/mL; p = 0.57),
while in the other ten patients (59%), was observed, a
significant increase of PRL levels ‘‘responder’’ (baseline vs
attacks: 101.5 ± 10.6 vs 205.6 ± 13.7 ng/mL; p \ 0.001).
In five of the ten ‘‘responder’’ patients, PRL levels
increased after TRH-test and induced severe attacks. We
observed no significant differences between PRL levels
after TRH-test and during migraine attacks (attacks vs
TRH-test: 205.6 ± 13.7 vs 198.4 ± 8.6 ng/mL; p = 0.75).
Four of these patients (n = 4/5, 80%) improved after
cabergoline treatment and one (n = 1/5, 20%) was
unchanged. In the other patients of the Group A (n = 13/
17, 76.4%), PRL increased after TRH test, but did not
induce severe attacks. Finally in all patients of the group B,
PRL scarcely increased after TRH-test and did not induce
severe attacks. The results of both groups are presented on
Tables 2 and 3.
Discussion
The presence of different types of headache in patients with
microprolactinoma has been described in the literature;
these included trigeminal autonomic cephalalgias (TACs)
[6], short-lasting unilateral neuralgiform headache attacks
with conjunctival injection and tearing (SUNCT) [7],
trigeminal neuralgia [9] and also migraine in two cases [8,
18]. It has also been previously suggested that the dopa-
mine–prolactin axis plays an important role in some
primary headaches notably migraine [19, 20]. Our data
confirm the hypothesis that most pituitary tumor-associated
headaches have a neuroendocrine mechanism and suggest
that the pathophysiology of pituitary-related tumor is more
complex than it is considered. The fact that some cases of
J Headache Pain (2008) 9:103–107 105
123
migraines can be dramatically improved or worsened by
DAs treatment, in the absence of any measurable change in
pituitary size, suggests that pituitary tumor-associated
migraine may be a biochemical-neuroendocrine problem
rather than a structural one. We observed that the mean
values of PRL levels, evaluated during two consecutive
attacks were higher in the majority of the patients with
migraine and microprolactinoma (group A); in fact, in ten
(59%) patients, the PRL levels were significantly higher
from baseline and in five of these, the TRH-test induced an
increase of PRL with severe migraine attacks (positive
response to TRH-test). TSH also increased in both groups,
but this rise is not significant. After treatment with
cabergoline, we registered a reduction of PRL levels in all
29 patients and in eight patients of the group A, we also
documented an improvement of migraine attacks. In four of
the eight patients, we observed a ‘‘positive response to
TRH-test’’. We suppose, this state cannot be explained
only by dopaminergic hypofunction, but also that prolac-
tinomas presence has abnormal secretory behavior
associated with lactotrope neoplastic alteration and/or
separation of tumor cell mass from usual hypothalamic
controls, with a consequent deregulation of PRL secretion
[21]. Dopaminergic dysfunction could also be the conse-
quence of a serotoninergic hyperfunction, because of the
inhibitory effect of serotonin on dopamine neurons. This
mechanism could also be the reason of increased TSH
secretion. Besides, in four patients of the group A,
cabergoline therapy induced a modification of headache
pattern from migraine to tension-type headache; the same
situation was described in two patients of a previous paper
[8]. Our data suggest that tension-type headache does not
seem to be influenced by hypothalamic–hypophysial axis
dysfunction; in fact, in our patients with tension-type
headache, PRL levels were unchanged both during head-
ache attacks and after TRH-test. High levels of PRL could
contribute to the development of certain pain disorders,
possibly including neuro-modulation processing of sensory
neurons in the trigeminal ganglia [22]. In our study, among
the five migraine patients with ‘‘positive response’’ to
TRH-test, four benefit from cabergoline treatment. Never-
theless, the small sample of patients does not allow to
establish if TRH-test is really able to identify those cases in
which dopaminergic system is directly involved in the
pathogenesis of migraine, may be through an hypersensi-
tivity of DA receptors mechanisms, as previously
suggested by some authors [10]. Further studies, on a large
sample of patients, are required to better investigate the
neuroendocrine mechanisms associated with pituitary
headache and if TRH-test could be used as screening test to
predict which patients with hyperprolactinemia and
migraine could benefit by DA therapy.
Table 2 PRL and TSH values in basal conditions, during headache
attacks, after TRH-test and after 3–6 months of cabergoline treatment
in 17 patients with migraine (group A) and 12 patients with tension-
type headache associated microprolactinoma (group B)
Group A Group B
PRL basal (ng/mL) 118.6 ± 10.8 106.9 ± 9.7
TSH basal (mUI/mL) 1.3 ± 0.5 1.4 ± 0.2
PRL during headachesa (ng/mL) 150.6 ± 16.8 108.7 ± 8.7
TSH during headaches (mUI/mL) 1.8 ± 0.2 1.6 ± 0.7
PRL after TRH-test (ng/mL) 161.3 ± 27.4 107 ± 9
TSH after TRH-test (mUI/mL) 7.1 ± 0.2 6.4 ± 0.8
PRL after cabergoline treatment (ng/
mL)
74 ± 6.8 68.2 ± 5.1
All values are in mean ± SD
PRL prolactin, group A microprolactinoma and migraine, group B
microprolactinoma and tension-type headache, TSH thyrotropin, TRH
thyrotropin-releasing-hormone
a Mean level at least in two attacks of headaches
Table 3 PRL levels and
clinical features of seven
‘‘no-responder’’ and ten
‘‘responder’’ patients of the
group A
No responder patients with a no
significant PRL increase during
migraine attacks; responder
patients with a significantl PRL
increase, during migraine
attacks; positive response to
TRH-test patients with increase
of PRL levels and migraine





No. (%) 7 (41) 10 (59)
PRL basal (ng/mL) 127 ± 21.4 101.5 ± 10.6
PRL during headachesa (ng/mL) 136.8 ± 19.8 205.6 ± 13.7
No. of patients with ‘‘positive response’’ after TRH-test 0/10 5/10
PRL after TRH-test (ng/mL) 144.8 ± 10.6 198.4 ± 8.6
PRL after DA treatment (ng/mL) 82 ± 5.4 67.5 ± 9.2
Outcome of headache after DA therapy, No. (%)
a (improvement) 3/7 (43) 5/10 (50)
b (worsening) 1/7 (14) 1/10 (10)
c (unchanged) 0/7 (0) 3/10 (30)
d (changed characteristics) 3/7 (43) 1/10 (10)
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